By Meghan Redshaw (Children's Health Defence)
 |
| Dr. Hooman Noorchashm |
Dr. Hooman Noorchashm, a surgeon, immunologist and patient safety advocate, wrote several letters to the U.S. Food and Drug Administration (FDA) shortly after the agency granted Pfizer and Moderna Emergency Use Authorization for their COVID vaccines.
In his letters, Noorchashm urged the FDA to require pre-screening for SARS-CoV-2 viral proteins in order to reduce COVID vaccine injuries and deaths.
Noorchashm also called on Pfizer and Modern to institute “clear recommendations to clinicians that they delay immunization in anyone recently recovering from COVID, as well as any known symptomatic or asymptomatic carriers — and to actively screen as many patients with high cardiovascular risk as is reasonably possible, in order to detect the presence of SARS-CoV-2, prior to vaccinating them.”
According to Noorchashm, it is scientifically established that once a person is naturally infected by a virus, antigens from that virus persist in the body for a long time after viral replication has stopped and clinical signs of infection have resolved.
When a vaccine reactivates an immune response in a recently infected person, the tissues harboring the persisting viral antigen are targeted, inflamed and damaged by the immune response.
“In the case of SARS-CoV-2, we know the virus naturally infects the heart, the inner lining of blood vessels, the lungs and the brain,” explained Noorchashm. “So these are likely to be some of the critical organs that will contain persistent viral antigens in the recently infected. Following reactivation of the immune system by a vaccine, these tissues can be expected to be targeted and damaged.”
In an interview with The Defender, Noorchashm said Greyson’s case reminded him of Everest Romney — the all-American basketball player who was hospitalized after his second dose of Pfizer for blood clots in his brain.
 |
| Greyson Follmer, an Ohio State University (OSU) student |
According to Noorchasm, both Romney and Greyson had acquired natural immunity because they’d been infected with COVID, and they likely did not stand to gain any benefit from a COVID vaccine.
Noorchashm explained:
“It’s a colossal error to vaccinate people who have had prior infections, and this is totally avoidable harm we are causing. Why are we rushing to vaccinate people who we know are immune and don’t stand to gain any benefit? If I do anything medically unnecessary to someone as a doctor, I’m opening them up to potential harm. If you’ve had a recent infection and you have viral antigens in your tissues, you can literally and immunologically cause tissue damage.”
Medical necessity is on the ground floor of everything doctors do in regards to safety, Noorchasm said. “If you want to be a safe hospital, doctor, practitioner or health agency you would not do anything that’s not necessary to people or fundamentally not beneficial. There’s only a probability of harm if there’s no medical necessity,” he said.
When asked specifically about myocarditis, Noorchashm said this is the original prediction and prognostication he made to the FDA.
Noorchashm said:
“We know that natural SARS CoV-2 virus can affect the heart. It can cause blood clots that can lead to heart attacks and strokes and myocarditis. The virus can trigger an immune response or inflammation to the heart. Anywhere the virus goes the immune system will target that tissue and cause problems. If you’ve had a prior infection and you have antigens in the tissues where the virus goes, like the heart, and you activate the immune response [with a vaccine], you’re going to activate damage.”
Noorchashm, who is pro-vaccine, said shots need to be spread out for people who are not immune and want to be vaccinated, and the FDA and CDC should think carefully about limiting the shot to one dose, especially in young people, or increasing the duration between first and second doses.
In his letter to the FDA, Noorchashm recommended actively screening as many patients with high cardiovascular risk as is reasonably possible, in order to detect the presence of SARS-CoV-2, prior to vaccinating them.
“If someone has a known history of COVID, there should not be any rush to get them vaccinated,” Noorchashm said. “That should be our national policy. If you’ve either had COVID, or you have laboratory evidence of immunity, you shouldn’t rush into getting vaccinated.”
---------------------------------------
Also See:
Understanding Vaccine Complications – Interview with Hooman Noorchashm, MD, PhD
https://drlindseyberkson.com/understanding-vaccine-complications-hooman-noorchashm-md-phd-216/
0 Comments